{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:17:27Z","timestamp":1783430247262,"version":"3.54.6"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA222793"],"award-info":[{"award-number":["R37CA222793"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"publisher","award":["U24CA171524"],"award-info":[{"award-number":["U24CA171524"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA195565"],"award-info":[{"award-number":["U01CA195565"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA154292"],"award-info":[{"award-number":["P01CA154292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"publisher","award":["R50CA211115"],"award-info":[{"award-number":["R50CA211115"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute at the National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA275764"],"award-info":[{"award-number":["T32CA275764"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Geoffrey Beene Cancer Research Center at Memorial Sloan Kettering Cancer Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy dose reductions are associated with poorer survival. To better understand the role of clinician- and facility-level factors in chemotherapy dosing, we conducted an analysis within a large, real-world cohort of women with stages I-IIIA breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our cohort included 8540 breast cancer patients receiving chemotherapy at Kaiser Permanente Northern California between 2006 and 2019. Patients were treated across 22 facilities by 198 clinicians. We evaluated associations between clinician- and facility-level factors related to dose reductions at the start of chemotherapy (first cycle dose proportion, FCDP, &amp;lt;90%) and throughout treatment (average relative dose intensity, ARDI, &amp;lt;90%). Prevalence ratios (PR) and corresponding 95% confidence intervals (CI) were estimated for the clinician and facility factors in relation to chemotherapy dose reductions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Factors associated with an increased likelihood of dose reduction were increased clinician years since medical school (FCDP\u2009&amp;lt;\u200990%: PR\u226530 vs. &amp;lt;10\u2009years = 1.78, P-trend\u2009=\u2009.03; ARDI\u2009&amp;lt;\u200990%: PR\u226530 vs &amp;lt;10\u2009years = 1.29, P-trend\u2009=\u2009.03) and treatment at less urban facilities (ARDI\u2009&amp;lt;\u200990%: PR&amp;lt;100% vs 100% urban = 1.38, P-trend\u2009=\u2009.002). Factors associated with a decreased likelihood of dose reduction were higher annual clinician volume of stage I-IIIA breast cancer patients (FCDP\u2009&amp;lt;\u200990%: PR\u226530 vs \u226415 patients = \u00a00.64, P-trend\u2009=\u2009.03; ARDI\u2009&amp;lt;\u200990%: PR\u226530 vs \u226415 patients = \u00a00.76, P-trend\u2009=\u2009.01), higher treatment facility annual volume of stage I-IIIA breast cancer patients (ARDI\u2009&amp;lt;\u200990%: PR\u2265200 vs &amp;lt;75 patients = 0.85, P-trend\u2009=\u2009.03), and a larger practice size (FCDP\u2009&amp;lt;\u200990%: PR\u226510 vs \u22645 oncologists = 0.53, P-trend\u2009=\u2009.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinician- and facility-level factors were associated with chemotherapy dose reductions. Practice-level changes, such as increasing breast cancer patient volumes and practice size, may support optimal dosing practices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag063","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:52:39Z","timestamp":1772283159000},"page":"1278-1289","source":"Crossref","is-referenced-by-count":1,"title":["Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast\u00a0cancer"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2120-2620","authenticated-orcid":false,"given":"Yashasvini","family":"Sampathkumar","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Zakaria","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-0788","authenticated-orcid":false,"given":"Kelli","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9962-7019","authenticated-orcid":false,"given":"Jenna","family":"Bhimani","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-8671","authenticated-orcid":false,"given":"Victoria S","family":"Blinder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2179-9816","authenticated-orcid":false,"given":"Rachael","family":"Burganowski","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-9754","authenticated-orcid":false,"given":"Isaac J","family":"Ergas","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9277-5002","authenticated-orcid":false,"given":"Grace B","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J","family":"Griggs","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology and Department of Health Management and Policy, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5239-0821","authenticated-orcid":false,"given":"Narre","family":"Heon","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5704-539X","authenticated-orcid":false,"given":"Tatjana","family":"Kolevska","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kaiser Permanente Medical Center , Vallejo, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1288-518X","authenticated-orcid":false,"given":"Yuriy","family":"Kotsurovskyy","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-3118","authenticated-orcid":false,"given":"Candyce H","family":"Kroenke","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]},{"name":"Department of Health Systems Science, Kaiser Permanente School of Medicine , Pasadena, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-6971","authenticated-orcid":false,"given":"Cecile A","family":"Laurent","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-9632","authenticated-orcid":false,"given":"Raymond","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]},{"name":"San Francisco Medical Center, Kaiser Permanente Northern California , San Francisco, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2417-3275","authenticated-orcid":false,"given":"Maria J","family":"Monroy-Iglesias","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6045","authenticated-orcid":false,"given":"Kanichi G","family":"Nakata","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5666-7994","authenticated-orcid":false,"given":"Sonia","family":"Persaud","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-4320","authenticated-orcid":false,"given":"Janise M","family":"Roh","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5498-7176","authenticated-orcid":false,"given":"Sara","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-9727","authenticated-orcid":false,"given":"Emily","family":"Valice","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-6081","authenticated-orcid":false,"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8789-2755","authenticated-orcid":false,"given":"Elisa V","family":"Bandera","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute , New Brunswick, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-7391","authenticated-orcid":false,"given":"Erin J","family":"Aiello Bowles","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-1175","authenticated-orcid":false,"given":"Lawrence H","family":"Kushi","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Pleasanton, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9124-5323","authenticated-orcid":false,"given":"Elizabeth D","family":"Kantor","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2026070708463494500_djag063-B1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6605268","article-title":"Chemotherapy for early-stage breast cancer: a brief history","volume":"101","author":"Verrill","year":"2009","journal-title":"Br J Cancer"},{"key":"2026070708463494500_djag063-B2","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/1097-0142(20000615)","article-title":"Developments in chemotherapy of breast cancer","volume":"88","author":"Hortobagyi","year":"2000","journal-title":"Cancer"},{"key":"2026070708463494500_djag063-B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13058-024-01822-9","article-title":"Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019","volume":"26","author":"Bhimani","year":"2024","journal-title":"Breast Cancer Res"},{"key":"2026070708463494500_djag063-B4","author":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer","year":"2024"},{"key":"2026070708463494500_djag063-B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070708463494500_djag063-B6","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"2026070708463494500_djag063-B7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026070708463494500_djag063-B8","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/s0959-8049(99)00259-2","article-title":"Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer","volume":"36","author":"Chang","year":"2000","journal-title":"Eur J Cancer"},{"key":"2026070708463494500_djag063-B9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","article-title":"Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices","volume":"13","author":"Denduluri","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070708463494500_djag063-B10","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/jco.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026070708463494500_djag063-B11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/jco.2006.08.3063","article-title":"Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy","volume":"25","author":"Griggs","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026070708463494500_djag063-B12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/a:1025481505537","article-title":"Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy","volume":"81","author":"Griggs","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"2026070708463494500_djag063-B13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","article-title":"Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy","volume":"100","author":"Shayne","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"2026070708463494500_djag063-B14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archinte.165.11.1267","article-title":"Undertreatment of obese women receiving breast cancer chemotherapy","volume":"165","author":"Griggs","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026070708463494500_djag063-B15","doi-asserted-by":"publisher","first-page":"iv80","DOI":"10.1093\/annonc\/mdu326.74","article-title":"The correlates of dose reduction in chemotherapy for patients with common cancers. a prospective study","volume":"25","author":"Bozcuk","year":"2014","journal-title":"Ann Oncol"},{"key":"2026070708463494500_djag063-B16","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1200\/jco.2007.25.18_suppl.6550","article-title":"Factors associated with reductions in chemotherapy dose intensity: impact of clinical, sociodemographic and practice setting","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026070708463494500_djag063-B17","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1200\/jco.2011.29.15_suppl.6106","article-title":"Relationship between physician characteristics and the use of newer chemotherapy for the treatment of colon cancer","volume":"29","author":"Becker","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026070708463494500_djag063-B18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1258\/jrsm.2010.100104","article-title":"Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice","volume":"103","author":"Hajjaj","year":"2010","journal-title":"J R Soc Med"},{"key":"2026070708463494500_djag063-B19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1176\/ps.2006.57.5.700","article-title":"Psychiatric decision making in the adoption of a new antipsychotic in Germany","volume":"57","author":"Hamann","year":"2006","journal-title":"Psychiatr Serv"},{"key":"2026070708463494500_djag063-B20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1186\/s12885-020-07355-6","article-title":"Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016","volume":"20","author":"Schwedhelm","year":"2020","journal-title":"BMC Cancer"},{"key":"2026070708463494500_djag063-B21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2753.1997.tb00067.x","article-title":"Patient, physician and presentational influences on clinical decision making for breast cancer: results from a factorial experiment","volume":"3","author":"McKinlay","year":"1997","journal-title":"J Eval Clin Pract"},{"key":"2026070708463494500_djag063-B22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/jpm.2006.0145","article-title":"Influence of patient and physician characteristics on percutaneous endoscopic gastrostomy tube decision-making","volume":"10","author":"Modi","year":"2007","journal-title":"J Palliat Med"},{"key":"2026070708463494500_djag063-B23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/00005650-199303000-00004","article-title":"Gender differences in practice style: a Dutch study of general practitioners","volume":"31","author":"Bensing","year":"1993","journal-title":"Med Care"},{"key":"2026070708463494500_djag063-B24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/154099903321154167","article-title":"Physician gender, patient gender, and primary care","volume":"12","author":"Franks","year":"2003","journal-title":"J Womens Health (Larchmt)"},{"key":"2026070708463494500_djag063-B25","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/cncr.31222","article-title":"Influence of provider factors and race on uptake of breast cancer gene expression profiling","volume":"124","author":"Reeder-Hayes","year":"2018","journal-title":"Cancer"},{"key":"2026070708463494500_djag063-B26","author":"Development and Update of Guidelines","year":"2024"},{"key":"2026070708463494500_djag063-B27","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/jco.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor\u2013positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026070708463494500_djag063-B28","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070708463494500_djag063-B29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070708463494500_djag063-B30","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008 298 women with early breast cancer in 26 randomised trials","volume":"393","author":"Gray","year":"2019","journal-title":"Lancet"},{"key":"2026070708463494500_djag063-B31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.13063\/2327-9214.1049","article-title":"The HMO research network virtual data warehouse: a public data model to support collaboration","volume":"2","author":"Ross","year":"2014","journal-title":"EGEMS (Wash DC)"},{"key":"2026070708463494500_djag063-B32","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ijc.35494","article-title":"Patient factors and modifications to intended chemotherapy for women with stages I-IIIA breast cancer","volume":"157","author":"Bhimani","year":"2025","journal-title":"Int J Cancer"},{"key":"2026070708463494500_djag063-B33","doi-asserted-by":"publisher","first-page":"e2300209","DOI":"10.1200\/cci.23.00209","article-title":"Methodology for using real-world data from electronic health records to assess chemotherapy administration in women with breast cancer","volume":"8","author":"Bhimani","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"2026070708463494500_djag063-B34","first-page":"5655","article-title":"A higher body mass index and fat mass are factors predictive of docetaxel dose intensity","volume":"33","author":"Gou\u00e9rant","year":"2013","journal-title":"Anticancer Res"},{"key":"2026070708463494500_djag063-B35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s12032-014-0881-z","article-title":"Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women","volume":"31","author":"Carroll","year":"2014","journal-title":"Med Oncol"},{"key":"2026070708463494500_djag063-B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1023\/a:1010635328299","article-title":"Are medical oncologists biased in their treatment of the large woman with breast cancer?","volume":"66","author":"Madarnas","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"2026070708463494500_djag063-B37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-023-07126-4","article-title":"Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system","volume":"203","author":"Kantor","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2026070708463494500_djag063-B38","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/cncr.23416","article-title":"Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice","volume":"112","author":"Greenman","year":"2008","journal-title":"Cancer"},{"key":"2026070708463494500_djag063-B39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1200\/OP.2024.20.10_suppl.99","article-title":"Associations between age at diagnosis and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer","volume":"20","author":"Bowles","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026070708463494500_djag063-B40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jgo.2014.12.002","article-title":"Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors","volume":"6","author":"Gajra","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"2026070708463494500_djag063-B41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/cancers13020331","article-title":"Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study","volume":"13","author":"Hwang","year":"2021","journal-title":"Cancers"},{"key":"2026070708463494500_djag063-B42","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-015-1696-9","article-title":"Representativeness of breast cancer cases in an integrated health care delivery system","volume":"15","author":"Gomez","year":"2015","journal-title":"BMC Cancer"},{"key":"2026070708463494500_djag063-B43","doi-asserted-by":"publisher","first-page":"028","DOI":"10.23937\/2643-4563\/1710028","article-title":"On the impact of premature termination of chemotherapy on relapse of breast cancer","volume":"4","author":"M\u00e4nnle","year":"2021","journal-title":"Int J Oncol Res"},{"key":"2026070708463494500_djag063-B44","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1200\/jco.2005.12.633","article-title":"Racial disparities in treatment and survival among women with early-stage breast cancer","volume":"23","author":"Hershman","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag063\/67235064\/djag063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1278\/67235064\/djag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1278\/67235064\/djag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:48:01Z","timestamp":1783428481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/7\/1278\/8506524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag063","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,4]]}}}